Why BridgeBio Pharma Stock Is Plunging Today
Shares of the small-cap biotech BridgeBio Pharma (NASDAQ: BBIO) were down by 7.2% on moderate volume as of 1:09 p.m. ET Thursday. The big loss came after JPMorgan Chase released a cautionary note on the biotech's experimental treatment of symptomatic transthyretin amyloidosis cardiomyopathy, or ATTR-CM, known as acoramidis.
ATTR-CM is a rare condition caused by a misfolded protein (transthyretin) accumulating in the pumping chambers of the heart. If left untreated, this heart ailment is often fatal.
Acoramidis is presently in phase 3 testing. BridgeBio previously announced that top-line data from this study should be available in late July.
Source Fool.com
JPMorgan Chase & Co. Aktie
310,10 €
1,49 %
Starkes Buy-Sentiment bei JPMorgan Chase & Co. mit 50 Buy- gegenüber 1 Sell-Einschätzungen.
Das niedrigere Kursziel von 303 € im Vergleich zum aktuellen Kurs von 310.1 € für JPMorgan Chase & Co. führt zu einem negativen Potenzial von -2.29%.
